CLDN17 and familial pancreatic carcinoma: Zhuang et al. have utilized the approach to identify five TAAbs in pancreatic cancer: anti-CLDN17, anti-KCNN3, anti-SLAMF7, anti-SLC22A11, and anti-OR51F2 [27].